Claro Advisors LLC Decreases Stake in Gilead Sciences, Inc. $GILD

Claro Advisors LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 70.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,202 shares of the biopharmaceutical company’s stock after selling 7,685 shares during the period. Claro Advisors LLC’s holdings in Gilead Sciences were worth $355,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. One Wealth Advisors LLC boosted its holdings in Gilead Sciences by 34.8% in the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after buying an additional 2,364 shares during the last quarter. Ariel Investments LLC lifted its position in shares of Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock valued at $48,229,000 after acquiring an additional 30,630 shares in the last quarter. Wealth Management Associates Inc. purchased a new position in shares of Gilead Sciences in the second quarter valued at approximately $255,000. Sivik Global Healthcare LLC boosted its stake in shares of Gilead Sciences by 25.0% in the second quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $5,544,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Covea Finance increased its position in shares of Gilead Sciences by 69.5% during the second quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company’s stock worth $5,732,000 after purchasing an additional 21,200 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $354,240.00. Following the completion of the transaction, the insider owned 110,193 shares of the company’s stock, valued at approximately $13,011,589.44. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the sale, the chief executive officer owned 581,203 shares of the company’s stock, valued at $69,389,826.17. This trade represents a 1.69% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 71,500 shares of company stock valued at $8,336,040. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 0.7%

Shares of Gilead Sciences stock opened at $123.40 on Friday. The stock has a 50 day moving average of $116.37 and a 200 day moving average of $112.07. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a market capitalization of $153.12 billion, a price-to-earnings ratio of 24.58, a PEG ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a fifty-two week low of $86.08 and a fifty-two week high of $124.61.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Analysts Set New Price Targets

A number of research analysts have weighed in on GILD shares. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective on the stock in a report on Tuesday, August 19th. Royal Bank Of Canada increased their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company a “sector perform” rating in a research report on Friday, October 31st. Rothschild & Co Redburn upped their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Morgan Stanley increased their price objective on shares of Gilead Sciences from $143.00 to $147.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Finally, Wells Fargo & Company boosted their target price on Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $127.82.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.